RecruitingNot ApplicableNCT06698159

Wide-Antral Pulmonary Vein Isolation in Atrial Fibrillation Ablation with a Single-shot Technique (WIDER-PVI)

Wide-Antral Pulmonary Vein Isolation in Patients Undergoing Atrial Fibrillation Ablation with a Single-shot Technique: the WIDER-PVI Trial


Sponsor

Hospital Universitario 12 de Octubre

Enrollment

440 participants

Start Date

Nov 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The WIDER PVI study is a multicentre randomized clinical trial to compare the efficacy of antral versus extended antral PVI in patients with paroxysmal or persistent AF undergoing this procedure using a cryoablation balloon capable of 28 mm diameter (antral isolation) or 31 mm diameter (extended antral isolation) applications. The aim is to evaluate an objective of superiority of the extended antral isolation strategy versus antral isolation in the recurrence of atrial tachyarrhythmias at 1-year follow-up, both in episodes of \>30 seconds duration and in overall arrhythmic load.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Age over 18 years old.
  • Previous diagnosis of paroxysmal or persistent atrial fibrillation less than 2 years after diagnosis.
  • Clinical indication to undergo a pulmonary vein isolation procedure using balloon cryoablation.

Exclusion Criteria12

  • Severe left atrial dilatation (indexed volume \>48 ml/m2 or area \>40 cm2 or indexed diameter \>3.0 cm/m2).
  • Previous endocardial or surgical ablation of atrial fibrillation.
  • Severe frailty (Clinical Frailty Scale score 7 or higher) or life expectancy less than 1 year.
  • Inability to understand or give informed consent.
  • Performance of other left atrial ablations in addition to pulmonary veins.
  • Need to use another catheter in addition to the cryoablation catheter to complete pulmonary vein isolation.
  • Contraindication to anticoagulation or intolerance to heparin.
  • Presence of intra-atrial thrombus.
  • Reversible cause of atrial fibrillation.
  • Severe mitral or aortic valve disease.
  • Congenital heart disease.
  • Pregnancy or the prospect of pregnancy in the next 12 months.

Interventions

DEVICECryoablation with cryoballoon 28 mm

Pulmonary vein isolation using 28 mm balloon cryoablation

DEVICECryoablation with cryoballoon 31 mm

Pulmonary vein isolation using 31 mm balloon cryoablation


Locations(17)

IRCCS Neuromed Mediterranean Neurological Institute

Pozzilli, Isernia, Italy

Casa di cura Villa dei Fiori

Acerra, Napoli, Italy

Poliambulanza Institute Hospital Foundation

Brescia, Italy

Ospedale Santa Maria Goretti

Latina, Italy

Clinica San Michele

Maddaloni, Italy

Fondazione IRCCS San Gerardo dei Tintori

Monza, Italy

Pellegrini Hospital

Napoli, Italy

Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova

Padua, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, University "Cattolica del Sacro Cuore"

Rome, Italy

S. Pietro Fatebenefratelli Hospital

Rome, Italy

HU Basurto

Bilbao, Spain

HU Virgen de las Nieves

Granada, Spain

HU Juan Ramón Jiménez

Huelva, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

HU Ramón y Cajal

Madrid, Spain

HU Virgen de la Victoria

Málaga, Spain

HU Virgen Macarena

Seville, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06698159


Related Trials